CymaBay Therapeutics, Inc.
CBAYDelisted Mar 22, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001042074
CymaBay Therapeutics, Inc. was delisted on Mar 22, 2024; its insiders filed their last Form 4 on Mar 22, 2024; 200 institutions reported holding it in 13F filings for Q4 2023, worth $2.71B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 200
- Q4 2023, +13 vs. previous quarter
- 13F value
- $2.71B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $31.1M
- No comparable prior period
- Net income, FY2023
- -$105.4M
- No comparable prior period
- Free cash flow, FY2023
- -$73.0M
- No comparable prior period
- Revenue, Q4 FY2023
- $57.0K
- No comparable prior period
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $105.4M (339.1% of revenue).
Superinvestors holding CBAY, Q4 2023
Go to the superinvestors tabNo superinvestor reported holding CBAY at the end of Q4 2023.
Latest insider trades
See all insider tradesOpen-market purchases and sales by CymaBay Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Dorling JanetDirector | SSale | −6.00K | $31.97 | −$191.8K | −100.0%0 after | 10b5-1 |
| Jan 22, 2024 (view filing) | Jan 19 | 3 days | McWherter CharlesPresident of R&D | SSale | −18.4K | $23.67 | −$435.7K | −55.1%15.0K after | 5 lots10b5-1 |
| Jan 16, 2024 (view filing) | Jan 16 | Same day | Menold DanielVice President, Finance | SSale | −10.0K | $23.58 | −$235.8K | −100.0%0 after | 10b5-1 |
| Jan 16, 2024 (view filing) | Jan 16 | Same day | Quinlan Paul TGeneral Counsel | SSale | −5.00K | $23.58 | −$117.9K | −100.0%0 after | |
| Jan 10, 2024 (view filing) | Jan 10 | Same day | Dorling JanetDirector | SSale | −6.00K | $23.86 | −$143.2K | −100.0%0 after | 10b5-1 |
| Dec 18, 2023 (view filing) | Dec 18 | Same day | McWherter CharlesPresident of R&D | SSale | −11.3K | $21.48 | −$243.5K | −43.0%15.0K after | 2 lots |
| Dec 15, 2023 (view filing) | Dec 15 | Same day | Menold DanielVice President, Finance | SSale | −21.5K | $21.99 | −$472.6K | −100.0%0 after | 2 lots10b5-1 |
| Dec 15, 2023 (view filing) | Dec 15 | Same day | Quinlan Paul TGeneral Counsel | SSale | −5.00K | $21.98 | −$109.9K | −100.0%0 after | |
| Dec 11, 2023 (view filing) | Dec 11 | Same day | Shah SujalChief Executive Officer | SSale | −64.9K | $20.00 | −$1.30M | −27.5%171.3K after | 2 lots10b5-1 |
| Dec 11, 2023 (view filing) | Dec 11 | Same day | Dorling JanetDirector | SSale | −6.00K | $20.07 | −$120.4K | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q4 2023
See all 200 holdersThe largest institutional positions in CymaBay Therapeutics, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 11,111,111 | $262.4M | 3.63% | +811,111+7.9% | Added |
| BlackRock Inc. | 9,610,239 | $227.0M | 0.01% | +1,818,243+23.3% | Added |
| Ra Capital Management, L.P. | 6,940,000 | $163.9M | 2.56% | 00.0% | Unchanged |
| Vanguard Group Inc | 6,306,149 | $149.0M | 0.00% | +558,562+9.7% | Added |
| Janus Henderson Group PLC | 6,103,797 | $144.2M | 0.09% | −699,687−10.3% | Reduced |
| Price T Rowe Associates Inc | 4,465,161 | $105.5M | 0.01% | +2,561,460+134.6% | Added |
| Perceptive Advisors LLC | 4,024,400 | $95.1M | 2.12% | −18,791−0.5% | Reduced |
| Jennison Associates LLC | 3,992,711 | $94.3M | 0.07% | +437,437+12.3% | Added |
| Franklin Resources Inc | 3,267,927 | $77.2M | 0.04% | −39,988−1.2% | Reduced |
| FMR LLC | 3,061,996 | $72.3M | 0.01% | +1,493,048+95.2% | Added |